AVN-397 is a 5-hydroxytryptamine subtype 6 receptor antagonist drug developed by Avineuro Pharmaceuticals Inc. that can potentially be used to treat Alzheimer's disease and general anxiety disorder (GAD). [1] [2] Avineuro announced that it would start Phase II clinical trials in 2009, and those trials are ongoing as of 2012. [3] [4] [5]
AVN-397 is a 5-hydroxytryptamine subtype 6 receptor antagonist drug developed by Avineuro Pharmaceuticals Inc. that can potentially be used to treat Alzheimer's disease and general anxiety disorder (GAD). [1] [2] Avineuro announced that it would start Phase II clinical trials in 2009, and those trials are ongoing as of 2012. [3] [4] [5]